2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-135588
    Raloxifene 6,4'-Bis-β-D-glucuronide 182507-20-6 98%
    Raloxifene 6,4'-Bis-β-D-glucuronide (compound IV) is a metabolite of Raloxifene. Raloxifene is a selective estrogen receptor antagonist for the prevention of osteoporosis.
    Raloxifene 6,4'-Bis-β-D-glucuronide
  • HY-135594
    4'-Raloxifene-β-D-glucopyranoside 334758-19-9 98%
    4'-Raloxifene-β-D-glucopyranoside, a metabolite of Raloxifene, is a benzothiophene glucuronidated at the 4' postion. 4'-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 4'-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 4'-Raloxifene-β-D-glucopyranoside, example 5, is extracted from patent US5567820A.
    4'-Raloxifene-β-D-glucopyranoside
  • HY-135595
    6-Raloxifene-β-D-glucopyranoside 334758-18-8 98%
    6-Raloxifene-β-D-glucopyranoside, a derivative of Raloxifene, is a benzothiophene glucuronidated at the 6' postion. 6-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 6-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 6'-Raloxifene-β-D-glucopyranoside, compound Ia, is extracted from patent US5567820A.
    6-Raloxifene-β-D-glucopyranoside
  • HY-135670
    Glycosidase-IN-1 170376-12-2 98%
    Glycosidase-IN-1 (Compound 9) is a glycosidase inhibitor synthesized from D-mannose. Glycosidase-IN-1 be used to synthesize some immunosuppressive agents and β-glucosidase inhibitors. Glycosidase-IN-1 has hypoglycemic activity.
    Glycosidase-IN-1
  • HY-13567A
    Bendamustine hydrochloride hydrate 1374784-02-7 98%
    Bendamustine hydrochloride hydrate (SDX-105 hydrate), a purine analogue, is a DNA cross-linking agent. Bendamustine hydrochloride hydrate activates DNA-damage stress response and apoptosis. Bendamustine hydrochloride hydrate has potent alkylating, anticancer and antimetabolite properties.
    Bendamustine hydrochloride hydrate
  • HY-135739
    Benzobarbital 744-80-9 98%
    Benzobarbital is an active low-toxicity inductor of the liver monooxygenase system. Benzobarbital raises cytochrome P-450 concentration. Benzobarbital can be used in the research of post-ischemic liver disease.
    Benzobarbital
  • HY-135956
    T3 Acyl glucuronide 910907-23-2 98%
    T3 Acyl glucuronide, an endogenous metabolite, is the acyl glucuronide formation of triiodothyronine (T3).
    T3 Acyl glucuronide
  • HY-136152
    MCHR1 antagonist 3 1069622-60-1 98%
    MCHR1 antagonist 3 is a potent the melanin-concentrating hormone receptor-1 (MCHR1) antagonist. MCHR1 antagonist 3 is used to regulate energy metabolism.
    MCHR1 antagonist 3
  • HY-136586
    Loperamide phenyl 1391052-94-0 99.9%
    Loperamide phenyl is an impurity of Loperamide (HY-B0418A). Loperamide is an opioid receptor agonist.
    Loperamide phenyl
  • HY-136696
    11-Deoxy-16,16-dimethyl-PGE2 53658-98-3 98%
    11-Deoxy-16,16-dimethyl-PGE2, a Prostaglandin E2 analog, is a EP2 and EP3 receptors agonist. 11-Deoxy-16,16-dimethyl-PGE2 protects proximal renal tubular epithelial cells from potent nephrotoxicity-induced cell damage by exerting anti-oxidative stress.
    11-Deoxy-16,16-dimethyl-PGE2
  • HY-137000
    4-Prenyloxyresveratrol 69065-16-3 98%
    4-Prenyloxyresveratrol, an oxyresveratrol derivative, shows potent tyrosinase inhibitory activity with an IC50 of 0.90 μM.
    4-Prenyloxyresveratrol
  • HY-137061
    AZ-GHS-22 1143020-91-0 98%
    AZ-GHS-22 is a potent, non-CNS penetrant GHS-R1a inverse agonist (IC50=0.77 nM).
    AZ-GHS-22
  • HY-13713A
    LY-377604 hydrochloride 204592-97-2 98%
    LY377604 hydrochloride is a human β3-adrenergic receptor agonist with an EC50 of 2.4 nM and also a β1- and β2-adrenergic receptor antagonist.
    LY-377604 hydrochloride
  • HY-137158
    16-Phenoxy tetranor Prostaglandin E2 54382-74-0 98%
    16-phenoxy tetranor PGE2 is the free acid form of sulprostone formed by the hydrolysis of the methylsulfonamide bond.1 16-phenoxy tetranor PGE2 is a minor metabolite of sulprostone found in human plasma after parenteral administration of the drug.
    16-Phenoxy tetranor Prostaglandin E2
  • HY-137178
    20α,22R-Dihydroxycholesterol 596-94-1 98%
    20α,22R-Dihydroxycholesterol is an endogenous metabolic intermediate. 20α,22R-Dihydroxycholesterol involved in the biosynthesis of cholesterol to steroid hormones.
    20α,22R-Dihydroxycholesterol
  • HY-137236
    6β-Hydroxy metandienone 33526-41-9 98%
    6β-Hydroxy metandienone is an anabolic androgenic steroid metabolite of Metandienone.
    6β-Hydroxy metandienone
  • HY-137310
    4-Hydroxy atorvastatin hemicalcium 265989-44-4
    4-Hydroxy atorvastatin hemicalcium is a metabolite of Atorvastatin (HY-B0589). Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin is metabolized by the cytochrome P450 (CYP) isoform CYP3A4 to form 4-hydroxy atorvastatin.
    4-Hydroxy atorvastatin hemicalcium
  • HY-137355
    15(S)-15-methyl Prostaglandin D2 85280-90-6 98%
    15(S)-15-methyl Prostaglandin D2 (15(S)-15-methyl PGD2) is a metabolically stable synthetic analog of PGD2. In contrast to PGD2, 15(S)-15-methyl PGD2 induces vasoconstriction and increases systemic blood pressure with much reduced inhibitory activity on ADP-induced platelet aggregation. It also exhibits strong antifertility activity in hamsters (200-fold more potent than PGD2).
    15(S)-15-methyl Prostaglandin D2
  • HY-137364
    Disulfamide 671-88-5 98%
    Disulfamide, an orally active diuretic, is a carbonic anhydrase inhibitor with the IC50 value of 0.07 μM. Disulfamide leads to diuresis by inhibiting carbonic anhydrase and preventing the reabsorption of sodium and bicarbonate in the proximal tubule.
    Disulfamide
  • HY-137388
    p-F-HHSiD 116679-83-5 98%
    p-F-HHSiD (p-Fluorohexahydrosiladifenidol) is a potent and selective M3 mAChR antagonist. p-F-HHSiD has antagonistic effects on other subtypes of the M receptor and the alpha1-adrenoceptor. p-F-HHSiD can be used for the researches of cancer, metabolic, neurological and cardiovascular disease such as, colon cancer, Alzheimer’s disease and diabetes.
    p-F-HHSiD
Cat. No. Product Name / Synonyms Application Reactivity